peptide fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
=== Gene location === IRAP is encoded by the LNPEP (leucyl and cystinyl aminopeptidase) gene, located on chromosome 5q15. This gene is ~75 kb in length and consists of 18 exons and 17 introns. According to ensembl.org, LNPEP has 5 transcripts but only one major expressed isoform (NM_005575.3).
After missing the first two matches of the 2014 season through suspension, Melksham played his first match of the year in the eighty-one point win against Carlton at the Melbourne Cricket Ground in round three. Playing a role in both the midfield and the back-line, Melksham played every match up to the sixty-four-point win against Collingwood at the Melbourne Cricket Ground in round seventeen; a drop in form throughout the year saw Melksham dropped for the round eighteen match against the Western Bulldogs at Etihad Stadium. After playing one match in the VFL, he returned for the eighteen point loss against Richmond at the Melbourne Cricket Ground in round twenty, and played the next week in the three-point win against West Coast at Etihad Stadium where he was substituted out of the match during the third quarter. He was omitted the next week for the match against Gold Coast at Etihad Stadium and missed the remainder of the year to finish with sixteen matches in total. Melksham played the first thirteen matches of the 2015 season, including his 100th AFL match in round four in the Anzac Day clash against Collingwood at the Melbourne Cricket Ground, before missing the round fifteen match against Melbourne at the Melbourne Cricket Ground due to a hamstring injury sustained at training.
===== Adverse effects ===== Mild or moderate adverse events are common, expressing symptoms like nausea, facial flushing, headache, and sunburn. Unlike flibanserin, bremelanotide induces fewer side effects and is not affected nor develops severe complications with alcohol. However, the drug slows down gastric emptying, which can cause an impact on oral drug uptake and the subsequent drug effectiveness. As activation of MC1R gives rise to hyperpigmentation, treatment dosage is at a maximum of eight doses per month. Besides, to minimize the chances of cardiovascular complications, the prescribed daily dosage is at one dose.
=== In the Mediterranean === The first biological evidence for reduced environments in the Mediterranean Sea was the presence of Lucinidae and Vesicomyidae bivalve shells cored on the top of the Napoli mud volcano (33°43′52″N 24°40′52″E; "Napoli" is only a name of a seamount. It is located south of Crete), located at 1,900 m deep on the Mediterranean Ridge in the subduction zone of the African Plate. This was followed by the description of a new Lucinidae bivalve species, Lucinoma kazani, associated with bacterial endosymbionts. In the southeastern Mediterranean, communities of polychaetes and bivalves were also found associated with cold seeps and carbonates near Egypt and the Gaza Strip at depths of 500–800 m, but no living fauna was collected. The first in situ observations of extensive living chemosynthetic communities in the eastern Mediterranean Sea prompted cooperation between biologists, geochemists, and geologists. During submersible dives, communities comprising large fields of small bivalves (dead and alive), large siboglinid tube worms, isolated or forming dense aggregations, large sponges, and associated endemic fauna were observed in various cold seep habitats associated with carbonate crusts at 1,700–2,000 m depth. Two mud volcano fields were first explored, one along the Mediterranean Ridge, where most of them were partially (Napoli, Milano mud volcanoes) or totally (Urania, Maidstone mud volcanoes) affected by brines, and the other on the Anaximander mounds south of Turkey.
Sources: en.wikipedia.org
=== Production === It is traditionally obtained by hydrolysis of various sources of protein, such as gelatin. It is obtained commercially by fermentation. In this way, 25-35 g/liter can be produced, using glucose as a carbon source.
CH3CH2OH + NAD+ → CH3CHO + NADH + H+ This allows the consumption of alcoholic beverages, but its evolutionary purpose is probably the breakdown of alcohols naturally contained in foods or produced by bacteria in the digestive tract. Another evolutionary purpose is reversible metabolism of retinol (vitamin A), an alcohol, to retinaldehyde, also known as retinal, which is then irreversibly converted into retinoic acid, which regulates expression of hundreds of genes.
The Somali Armed Forces (SAF) are the military forces of the Federal Republic of Somalia. Headed by the President as Commander in Chief, they are constitutionally mandated to ensure the nation's sovereignty, independence and territorial integrity. The SAF was initially made up of the Army, Navy, Air Force, Police Force and the National Security Service. In the post-independence period, it grew to become among the larger militaries on the continent. The subsequent outbreak of the civil war in 1991 led to the disbandment of the Somali National Army. In 2004, the gradual process of reconstituting the military was put in motion with the establishment of the Transitional Federal Government (TFG). The Somali Armed Forces are now overseen by the Ministry of Defence of the Federal Government of Somalia, formed in mid-2012. In January 2013, the Somali federal government also reopened the national intelligence service in Mogadishu, renaming the agency the National Intelligence and Security Agency (NISA). The Somaliland and Puntland regional governments maintain their own security and police forces.
Capsaicin extracted from chilies is used in pepper sprays and some tear gas formulations as a chemical irritant, for use as less-lethal weapons for control of unruly individuals or crowds. Such products have considerable potential for misuse, and may cause injury or death. In Africa and Asia, elephants nightly destroy crops and endanger people. Chilis are effective at keeping elephants away, as capsaicin irritates their large and sensitive olfactory and nasal system. Farmers can plant a few rows of the fruit around valuable crops; or they may burn chili dung bombs, bricks of dung and chili, creating a noxious smoke. Birds do not have the same sensitivity to capsaicin as mammals, as they lack a specific pain receptor. Some species in the chili peppers' natural range eat the fruits, possibly dispersing the seeds.
== Systemic diseases == Myopathies in systemic disease results from several different disease processes including endocrine, inflammatory, paraneoplastic, infectious, drug- and toxin-induced, critical illness myopathy, metabolic, collagen-related, and myopathies with other systemic disorders. Patients with systemic myopathies often present acutely or subacutely. On the other hand, familial myopathies or dystrophies generally present in a chronic fashion with exceptions of metabolic myopathies, in which symptoms on occasion can be precipitated acutely. Metabolic myopathies, which affect the production of ATP within the muscle cell, typically present with dynamic (exercise-induced) rather than static symptoms. Most of the inflammatory myopathies can have a chance association with malignant lesion; the incidence appears to be specifically increased only in patients with dermatomyositis. There are many types of myopathy. ICD-10 codes are provided here where available.
Sources: en.wikipedia.org
== Further reading == Schaefer, Charles (1999). "'Selling at a Wash:' Competition and the Indian Merchant Community in Aden Crown Colony". Comparative Studies of South Asia, Africa and the Middle East. 19 (2): 16–23. doi:10.1215/1089201X-19-2-16.
== Examples == Examples of dough conditioners include ascorbic acid, distilled monoglycerides, citrate ester of monoglycerides, diglycerides, ammonium chloride, enzymes, diacetyl tartaric acid ester of monoglycerides or DATEM, potassium bromate, potassium iodate, calcium salts such as calcium iodate, L-cystine, L-cysteine HCl, glycerol monostearate, azodicarbonamide, sodium stearoyl lactylate, sucrose palmitate or other sucrose esters, polyoxyethylene sorbitan monostearate or polysorbate, soybean lecithin, and soybean lecithin enriched with lysophospholipids. Less processed dough conditioners include sprouted- or malted-grain flours, soy, milk, wheat germ, eggs, potatoes, gluten, yeast, and extra kneading. Malted, diastatic flours are not typically added by manufacturers to whole-wheat flours.
== External links == Dagli AI, Mathews J, Williams CA (May 2025). "Angelman Syndrome". In Adam MP, Bick S, Mirzaa GM, et al. (eds.). GeneReviews® [Internet]. University of Washington, Seattle. PMID 20301323. NBK1144. OMIM entries on Angelman syndrome UniProt entry for ubiquitin "7.340 Ubiquitination: The Proteasome and Human Disease". MIT OpenCourseWare. 2004. Notes from MIT course. Ubiquitin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
=== Elections === In 1988, incumbent Republican congressman Jim Jeffords decided to run for the U.S. Senate, vacating the House seat representing Vermont's at-large congressional district. Former lieutenant governor Peter P. Smith won the House election with a plurality, securing 41% of the vote. Sanders, who ran as an independent, placed second with 38% of the vote, while Democratic state representative Paul N. Poirier placed third with 19%. Two years later, he ran for the seat again and defeated Smith by a margin of 56% to 39%. Sanders was the first independent elected to the U.S. House of Representatives since Frazier Reams of Ohio won his second term in 1952, as well as the first socialist elected to the House since Vito Marcantonio, from the American Labor Party, who won his last term in 1948. Sanders was a representative from 1991 until he became a senator in 2007, winning reelection by large margins except during the 1994 Republican Revolution, when he won by 3%, with 50% of the vote.
==== Grafting through ==== Not like the grafting from and grafting to approach which can conjugate several polymers onto one protein core, the grafting through approach enables several proteins to connect to one polymer chain due to the multivalent nature of protein.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.